Ida Aronchik
Company: Revolution Medicines Inc.
Job title: Senior Director - Translational Sciences
Seminars:
RMC-0708: First-in-Class Mutant-Selective RAS(ON) Inhibitor for KRASQ61H Cancers 4:45 pm
KRASQ61H mutant cancers represent an unmet medical need and include common solid tumor histotypes such NSCLC, PDAC, and CRC. RMC-0708 is a first-in-class, orally bioavailable, mutant-selective, and non-covalent inhibitor of KRASQ61H(ON). RMC-0708 potently suppresses p-ERK and proliferation in KRASQ61H mutant cancer cells while displaying selectivity against wildtype KRAS. RMC-0708 demonstrates anti-tumor activity in various preclinical…Read more
day: Conference Day One
Make it a Combo Meal: Exploring Combination Therapies that Assist RAS-Targeted Drugs in Ensuring Cancer Free Survival 3:01 pm
Given the RAS pathway’s importance to normal cell homeostasis, it has evolved to be a naturally robust pathway that is difficult to disrupt. For a few years now, it has become clear that RAStargeted drugs work more effectively when combined with other therapies, such as inhibitors up/ downstream of RAS, immune checkpoint inhibitors and various…Read more
day: Workshop C
Assessing Biomarkers & Genomic Data to Inform Patient Selection & Stratification in Clinical Trials 12:01 pm
As with any trial, understanding patient profiles to create classification and stratification criteria is extremely important for successful clinical design. Even more so, for RAS, pre-empting patient reactions to drugs, possible resistance mechanisms, and then accurately assessing the drug’s activity in each patient, is essential. Biomarkers and genomic data are some of the most reliable…Read more
day: Workshop E